Last reviewed · How we verify
SUCLEAR®
SUCLEAR is a photodynamic therapy agent that generates reactive oxygen species upon light activation to selectively destroy cancer cells.
SUCLEAR is a photodynamic therapy agent that generates reactive oxygen species upon light activation to selectively destroy cancer cells. Used for Solid tumors (Phase 3 development).
At a glance
| Generic name | SUCLEAR® |
|---|---|
| Also known as | oral sulfate solution; OSS, |
| Sponsor | National Cancer Center, Korea |
| Drug class | Photodynamic therapy agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SUCLEAR functions as a photosensitizer that accumulates in tumor tissue and, when activated by specific wavelengths of light, produces singlet oxygen and other reactive oxygen species that cause direct cytotoxic damage to cancer cells and associated vasculature. This mechanism allows for localized tumor destruction with reduced systemic toxicity compared to conventional chemotherapy.
Approved indications
- Solid tumors (Phase 3 development)
Common side effects
- Photosensitivity
- Skin reactions at treatment site
- Pain at injection site
Key clinical trials
- Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel Preparation (PHASE3)
- Comparison Between OSS and 2L PEG/Asc for Bowel Preparation of Elderly People (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUCLEAR® CI brief — competitive landscape report
- SUCLEAR® updates RSS · CI watch RSS
- National Cancer Center, Korea portfolio CI